公开(公告)号：US20220111043A1

公开(公告)日：2022-04-14

申请号：US17277906

申请日：2019-09-19

Applicant: LAVA THERAPEUTICS B.V.

Inventor： Johannes Jelle VAN DER VLIET ,  Roeland LAMERIS ,  Tanja Denise DE GRUIJL ,  Paul Willem Henri Ida PARREN

IPC: A61K39/395 ,  A61P35/00

Abstract: The present invention relates to the field of immunology, more in particular to the field of binding moieties and/or immunoglobulins which bind to human CD1d, including antibodies and fragments thereof that modify CD1d-mediated biological functions such as enhanced activation and reduced activation of CD1d-restricted T cells, including the natural killer T-cells and gamma-delta T-cells, and modulation of the function of cells expressing CD1d. The invention also relates to bi-, tri- or multi-specific immunoglobulins that bind to CD1d and a gamma-delta TCR and/or a tumor target. The invention further relates to pharmaceutical preparations and use of such mono-, bi-, and tri- or multi-specific binding moieties and/or immunoglobulins in the treatment of diseases or disorders.

公开(公告)号：US20210371525A1

公开(公告)日：2021-12-02

申请号：US17277984

申请日：2019-09-19

Applicant: LAVA THERAPEUTICS B.V.

Inventor： Iris DE WEERDT ,  Arnon Philip KATER ,  Paul Willem Henri Ida PARREN ,  Tanja Denise DE GRUIJL ,  Johannes Jelle VAN DER VLIET ,  Roeland LAMERIS

IPC: C07K16/28 ,  A61P35/02

Abstract: The present invention relates to novel methods for the treatment of hematological malignancies. In particular, the invention relates to the treatment of hematological malignancies using antibodies comprising a first binding moiety that is able to bind human CD1d and a second binding moiety that is able to bind the human Vγ9Vδ2-TCR.